Biophysics of cell membrane lipids in cancer drug resistance: Implications for drug transport and drug delivery with nanoparticles

Advanced Drug Delivery Reviews

Volumn 65, Issue 13-14, 2013, Pages 1686-1698

  Peetla, Chiranjeevi ^a   Vijayaraghavalu, Sivakumar ^a   Labhasetwar, Vinod ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Endocytosis; Membrane fluidity; Multidrug resistance; Nanomedicine; P glycoprotein efflux

Indexed keywords

BIOPHYSICAL PROPERTIES; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; MEMBRANE BIOPHYSICS; MEMBRANE FLUIDITY; MEMBRANE TRAFFICKING; MULTIDRUG RESISTANCE; P-GLYCOPROTEIN;

BIOCHEMISTRY; BIOPHYSICS; CELL DEATH; CELL MEMBRANES; DRUG DELIVERY; GLYCOPROTEINS; MEDICAL NANOTECHNOLOGY; MOLECULAR BIOLOGY; NANOPARTICLES;

LIPIDS;

5 AZA 2' DEOXYCYTIDINE; CERAMIDE; CETRIMIDE; CHOLESTEROL; CISPLATIN; DOXORUBICIN; LINOLENIC ACID; MEMBRANE LIPID; MULTIDRUG RESISTANCE PROTEIN; NANOCARRIER; NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; SPHINGOMYELIN; TAUROCHENODEOXYCHOLIC ACID; VERAPAMIL; VINBLASTINE; VORINOSTAT;

APOPTOSIS; BLADDER CARCINOMA; BREAST CANCER; CELL MEMBRANE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG TRANSPORT; ENDOCYTOSIS; HUMAN; IC 50; LIPID BILAYER; LIPID COMPOSITION; LIPOGENESIS; MEMBRANE TRANSPORT; NEOPLASM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ADR; ADRIAMYCIN-RESISTANT; AFM; APOPTOSIS; ATOMIC FORCE MICROSCOPIC; CETYLTRIMETHYLAMMONIUM BROMIDE; CTAB; DIDODECYLDIMETHYLAMMONIUM BROMIDE; DMAB; ENDOCYTIC RECYCLING COMPARTMENT; ENDOCYTOSIS; ERC; ERCC1; EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1; GCS; GLUCOSYLCERAMIDE SYNTHASE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUVECS; MDR; MEMBRANE FLUIDITY; MULTIDRUG RESISTANCE; NANOMEDICINE; NANOPARTICLE; NP; P-GLYCOPROTEIN EFFLUX; P-GP; PC; PE; PERMEABILITY GLYCOPROTEIN; PHOSPHATIDYL ETHANOLAMINE; PHOSPHATIDYL SERINE; PHOSPHOCHOLINE; PS; SM; SMASE; SPHINGOMYELIN; SPHINGOMYELINASE; TAT; TRANS-ACTIVATING TRANSCRIPTIONAL;

ANIMALS; BIOLOGICAL TRANSPORT; BIOPHYSICAL PROCESSES; DRUG CARRIERS; DRUG RESISTANCE; ENDOCYTOSIS; HUMANS; MEMBRANE LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS;

EID: 84888200889     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2013.09.004     Document Type: Review

References (134)

1. Solyanik G.I. Multifactorial nature of tumor drug resistance. Exp. Oncol. 2010, 32:181-185.
2. Lyman G.H. Weight-based chemotherapy dosing in obese patients with cancer: back to the future. J. Oncol. Pract. 2012, 8:e62-e64.
3. Goldie J.H., Coldman A.J. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res. 1984, 44:3643-3653.
4. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
5. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr. Med. Chem. 2006, 13:1859-1876.
6. Larsen A.K., Skladanowski A. Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta 1998, 1400:257-274.
7. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
8. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 2011, 14:150-163.
9. Qiao L., Wong B.C. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist. Updat. 2009, 12:55-64.
10. Knappskog S., Lonning P.E. P53 and its molecular basis to chemoresistance in breast cancer. Expert Opin. Ther. Targets 2012, 16(Suppl. 1):S23-S30.
11. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
12. Lo P.K., Sukumar S. Epigenomics and breast cancer. Pharmacogenomics 2008, 9:1879-1902.
13. Vijayaraghavalu S., Dermawan J.K., Cheriyath V., Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol. Pharm. 2013, 10:337-352.
14. Vilmar A., Sorensen J.B. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature. Lung Cancer 2009, 64:131-139.
15. Vijayaraghavalu S., Peetla C., Lu S., Labhasetwar V. Epigenetic modulation of the biophysical properties of drug-resistant cell lipids to restore drug transport and endocytic functions. Mol. Pharm. 2012, 9:2730-2742.
16. Milane L., Ganesh S., Shah S., Duan Z.F., Amiji M. Multi-modal strategies for overcoming tumor drug resistance: hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 2011, 155:237-247.
17. Hu C.M., Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Pharmacol. 2012, 83:1104-1111.
18. Gao Z., Zhang L., Sun Y. Nanotechnology applied to overcome tumor drug resistance. J. Control. Release 2012, 162:45-55.
19. Gao J., Feng S.S., Guo Y. Nanomedicine against multidrug resistance in cancer treatment. Nanomedicine (Lond.) 2012, 7:465-468.
20. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 2006, 580:2903-2909.
21. Fesik S.W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer 2005, 5:876-885.
22. Lefranc F., Facchini V., Kiss R. Proautophagic drugs: a novel means to combat apoptosis- resistant cancers, with a special emphasis on glioblastomas. Oncologist 2007, 12:1395-1403.
23. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., He H. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
24. Yague E., Higgins C.F., Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther. 2004, 11:1170-1174.
25. Huang Y., Anderle P., Bussey K.J., Barbacioru C., Shankavaram U., Dai Z., Reinhold W.C., Papp A., Weinstein J.N., Sadee W. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res. 2004, 64:4294-4301.
26. Wu H., Hait W.N., Yang J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res. 2003, 63:1515-1519.
27. Dipaola R.S., Aisner J. Overcoming bcl-2- and p53-mediated resistance in prostate cancer. Semin. Oncol. 1999, 26:112-116.
28. Xiang J., Gomez-Navarro J., Arafat W., Liu B., Barker S.D., Alvarez R.D., Siegal G.P., Curiel D.T. Pro-apoptotic treatment with an adenovirus encoding Bax enhances the effect of chemotherapy in ovarian cancer. J. Gene Med. 2000, 2:97-106.
29. Escriba P.V., Gonzalez-Ros J.M., Goni F.M., Kinnunen P.K., Vigh L., Sanchez-Magraner L., Fernandez A.M., Busquets X., Horvath I., Barcelo-Coblijn G. Membranes: a meeting point for lipids, proteins and therapies. J. Cell. Mol. Med. 2008, 12:829-875.
30. Preetha A., Banerjee R., Huilgol N. Surface activity, lipid profiles and their implications in cervical cancer. J. Cancer Res. Ther. 2005, 1:180-186.
31. Preetha A., Banerjee R., Huilgol N. Dynamic surface tensiometry of tissues using Langmuir films. Colloids Surf. B Biointerfaces 2005, 40:35-43.
32. Ran S., Downes A., Thorpe P.E. Increased exposure of anionic phospholipids on the surface of tumor blood vessels. Cancer Res. 2002, 62:6132-6140.
33. Ewers H., Helenius A. Lipid-mediated endocytosis. Cold Spring Harb. Perspect. Biol. 2011, 3:a004721.
34. Mcmahon H.T., Gallop J.L. Membrane curvature and mechanisms of dynamic cell membrane remodelling. Nature 2005, 438:590-596.
35. Mukherjee S., Maxfield F.R. Role of membrane organization and membrane domains in endocytic lipid trafficking. Traffic 2000, 1:203-211.
36. Hendrich A.B., Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr. Cancer Drug Targets 2003, 4:23-30.
37. Pallares-Trujillo J., Lopez-Soriano F.J., Argiles J.M. Lipids: a key role in multidrug resistance? (Review). Int. J. Oncol. 2000, 16:783-798.
38. Phillips R., Ursell T., Wiggins P., Sens P. Emerging roles for lipids in shaping membrane-protein function. Nature 2009, 459:379-385.
39. Vigh L., Escriba P.V., Sonnleitner A., Sonnleitner M., Piotto S., Maresca B., Horvath I., Harwood J.L. The significance of lipid composition for membrane activity: new concepts and ways of assessing function. Prog. Lipid Res. 2005, 44:303-344.
40. Zhang T., Saghatelian A. Emerging roles of lipids in BCL-2 family-regulated apoptosis. Biochim. Biophys. Acta 2013, 1831:1542-1554.
41. Gruner S.M., Cullis P.R., Hope M.J., Tilcock C.P. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu. Rev. Biophys. Biophys. Chem. 1985, 14:211-238.
42. Cullis P.R., De Kruijff B. Lipid polymorphism and the functional roles of lipids in biological membranes. Biochim. Biophys. Acta 1979, 559:399-420.
43. Israelachvili J.N., Marcelja S., Horn R.G. Physical principles of membrane organization. Q. Rev. Biophys. 1980, 13:121-200.
44. Frolov V.A., Shnyrova A.V., Zimmerberg J. Lipid polymorphisms and membrane shape. Cold Spring Harb. Perspect. Biol. 2011, 3:a004747.
45. Cullis P.R., Hope M.J., Tilcock C.P.S. Lipid polymorphism and the roles of lipids in membranes. Chem. Phys. Lipids 1986, 40:127-144.
46. Vandijck P.W.M. Negatively charged phospholipids and their position in the cholesterol affinity sequence. Biochim. Biophys. Acta 1979, 555:89-101.
47. Mayer L.D., Bally M.B., Cullis P.R. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. Biochim. Biophys. Acta 1986, 857:123-126.
48. Saeki T., Shimabuku A.M., Ueda K., Komano T. Specific drug binding by purified lipid- reconstituted P-glycoprotein: dependence on the lipid composition. Biochim. Biophys. Acta 1992, 1107:105-110.
49. Callaghan R., Stafford A., Epand R.M. Increased accumulation of drugs in a multidrug resistant cell-line by alteration of membrane biophysical properties. Biochim. Biophys. Acta 1993, 1175:277-282.
50. Ramu A., Glaubiger D., Magrath I.T., Joshi A. Plasma membrane lipid structural order in doxorubicin-sensitive and -resistant P388 cells. Cancer Res. 1983, 43:5533-5537.
51. Ramu A., Glaubiger D., Weintraub H. Differences in lipid composition of doxorubicin-sensitive and -resistant P388 cells. Cancer Treat. Rep. 1984, 68:637-641.
52. May G.L., Wright L.C., Dyne M., Mackinnon W.B., Fox R.M., Mountford C.E. Plasma membrane lipid composition of vinblastine sensitive and resistant human leukaemic lymphoblasts. Int. J. Cancer 1988, 42:728-733.
53. Jin M.S., Oldham M.L., Zhang Q., Chen J. Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans. Nature 2012, 490:566-569.
54. Clay A.T., Sharom F.J. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry (Mosc.) 2013, 52:343-354.
55. De Milito A., Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol. 2005, 1:779-786.
56. Hasmann M., Valet G.K., Tapiero H., Trevorrow K., Lampidis T. Membrane potential differences between adriamycin-sensitive and -resistant cells as measured by flow cytometry. Biochem. Pharmacol. 1989, 38:305-312.
57. Lampidis T.J., Castello C., Del Giglio A., Pressman B.C., Viallet P., Trevorrow K.W., Valet G.K., Tapiero H., Savaraj N. Relevance of the chemical charge of rhodamine dyes to multiple drug resistance. Biochem. Pharmacol. 1989, 38:4267-4271.
58. Callaghan R., Van Gorkom L.C., Epand R.M. A comparison of membrane properties and composition between cell lines selected and transfected for multi-drug resistance. Br. J. Cancer 1992, 66:781-786.
59. Peetla C., Bhave R., Vijayaraghavalu S., Stine A., Kooijman E., Labhasetwar V. Drug resistance in breast cancer cells: biophysical characterization of and doxorubicin interactions with membrane lipids. Mol. Pharm. 2010, 7:2334-2348.
60. Hindenburg A.A., Baker M.A., Gleyzer E., Stewart V.J., Case N., Taub R.N. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res. 1987, 47:1421-1425.
61. Meschini S., Molinari A., Calcabrini A., Citro G., Arancia G. Intracellular localization of the antitumour drug adriamycin in living cultured cells: a confocal microscopy study. J. Microsc. 1994, 176:204-210.
62. Simon S.M., Schindler M. Cell biological mechanisms of multidrug resistance in tumors. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:3497-3504.
63. Simon S., Roy D., Schindler M. Intracellular pH and the control of multidrug resistance. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1128-1132.
64. Raghunand N., Martinez-Zaguilan R., Wright S.H., Gillies R.J. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem. Pharmacol. 1999, 57:1047-1058.
65. Warren L., Jardillier J.C., Ordentlich P. Secretion of lysosomal enzymes by drug-sensitive and multiple drug-resistant cells. Cancer Res. 1991, 51:1996-2001.
66. Keizer H.G., Joenje H. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J. Natl. Cancer Inst. 1989, 81:706-709.
67. Sognier M.A., Zhang Y., Eberle R.L., Sweet K.M., Altenberg G.A., Belli J.A. Sequestration of doxorubicin in vesicles in a multidrug-resistant cell-line (Lz-100). Biochem. Pharmacol. 1994, 48:391-401.
68. Liang X.J., Mukherjee S., Shen D.W., Maxfield F.R., Gottesman M.M. Endocytic recycling compartments altered in cisplatin-resistant cancer cells. Cancer Res. 2006, 66:2346-2353.
69. Rauch C. Toward a mechanical control of drug delivery. On the relationship between Lipinski's 2nd rule and cytosolic pH changes in doxorubicin resistance levels in cancer cells: a comparison to published data. Eur. Biophys. J. 2009, 38:829-846.
70. Victorov A.V., Janes N., Taraschi T.F., Hoek J.B. Packing constraints and electrostatic surface potentials determine transmembrane asymmetry of phosphatidylethanol. Biophys. J. 1997, 72:2588-2598.
71. 13C-NMR probe for reporting packing constraints in phospholipid membranes. Biochim. Biophys. Acta 1996, 1283:151-162.
72. Petrache H.I., Zemb T., Belloni L., Parsegian V.A. Salt screening and specific ion adsorption determine neutral-lipid membrane interactions. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:7982-7987.
73. Petrache H.I., Zemb T., Parsegian V.A. Specific salt adsorption, screening of dispersion forces and swelling of zwitterionic bilayers induced by addition salt. Abstr. Pap. Am. Chem. Soc. 2005, 229:U669-U669.
74. Petelska A.D., Figaszewski Z.A. Effect of pH on the interfacial tension of bilayer lipid membrane formed from phosphatidylcholine or phosphatidylserine. Biochim. Biophys. Acta 2002, 1561:135-146.
75. Petelska A.D., Figaszewski Z.A. Effect of pH on the interfacial tension of lipid bilayer membrane. Biophys. J. 2000, 78:812-817.
76. Petelska A.D., Figaszewski Z.A. pH Effect of the sphingomyelin membrane interfacial tension. J. Membr. Biol. 2009, 230:11-19.
77. Ambudkar S.V., Kim I.W., Sauna Z.E. The power of the pump: mechanisms of action of P-glycoprotein (ABCB1). Eur. J. Pharm. Sci. 2006, 27:392-400.
78. Eckford P.D., Sharom F.J. ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 2009, 109:2989-3011.
79. Ferte J. Analysis of the tangled relationships between P-glycoprotein-mediated multidrug resistance and the lipid phase of the cell membrane. Eur. J. Biochem. 2000, 267:277-294.
80. Clay A.T., Sharom F.J. Lipid bilayer properties control membrane partitioning, binding, and transport of p-glycoprotein substrates. Biochemistry 2013, 52:343-354.
81. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
82. Brown R.E. Sphingolipid organization in biomembranes: what physical studies of model membranes reveal. J. Cell Sci. 1998, 111(Pt 1):1-9.
83. Raviv Y., Pollard H.B., Bruggemann E.P., Pastan I., Gottesman M.M. Photosensitized labeling of a functional multidrug transporter in living drug-resistant tumor cells. J. Biol. Chem. 1990, 265:3975-3980.
84. Callaghan R., Berridge G., Ferry D.R., Higgins C.F. The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface. Biochim. Biophys. Acta 1997, 1328:109-124.
85. Doige C.A., Yu X.H., Sharom F.J. The effects of lipids and detergents on ATPase-active P-glycoprotein. Biochim. Biophys. Acta 1993, 1146:65-72.
86. Belli S., Elsener P.M., Wunderli-Allenspach H., Kramer S.D. Cholesterol-mediated activation of P-glycoprotein: distinct effects on basal and drug-induced ATPase activities. J. Pharm. Sci. 2009, 98:1905-1918.
87. Bucher K., Belli S., Wunderli-Allenspach H., Kramer S.D. P-glycoprotein in proteoliposomes with low residual detergent: the effects of cholesterol. Pharm. Res. 2007, 24:1993-2004.
88. Eckford P.D., Sharom F.J. Interaction of the P-glycoprotein multidrug efflux pump with cholesterol: effects on ATPase activity, drug binding and transport. Biochemistry 2008, 47:13686-13698.
89. Garrigues A., Escargueil A.E., Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10347-10352.
90. Romsicki Y., Sharom F.J. The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter. Biochemistry 1999, 38:6887-6896.
91. Schuldes H., Dolderer J.H., Zimmer G., Knobloch J., Bickeboller R., Jonas D., Woodcock B.G. Reversal of multidrug resistance and increase in plasma membrane fluidity in CHO cells with R-verapamil and bile salts. Eur. J. Cancer 2001, 37:660-667.
92. Wilson T.R., Johnston P.G., Longley D.B. Anti-apoptotic mechanisms of drug resistance in cancer. Curr. Cancer Drug Targets 2009, 9:307-319.
93. Hannun Y.A., Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 2002, 277:25847-25850.
94. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 2002, 110:3-8.
95. Kolesnick R.N., Goni F.M., Alonso A. Compartmentalization of ceramide signaling: physical foundations and biological effects. J. Cell. Physiol. 2000, 184:285-300.
96. Veiga M.P., Arrondo J.L., Goni F.M., Alonso A. Ceramides in phospholipid membranes: effects on bilayer stability and transition to nonlamellar phases. Biophys. J. 1999, 76:342-350.
97. Megha, London E. Ceramide selectively displaces cholesterol from ordered lipid domains (rafts): implications for lipid raft structure and function. J. Biol. Chem. 2004, 279:9997-10004.
98. Sot J., Ibarguren M., Busto J.V., Montes L.R., Goni F.M., Alonso A. Cholesterol displacement by ceramide in sphingomyelin-containing liquid-ordered domains, and generation of gel regions in giant lipidic vesicles. FEBS Lett. 2008, 582:3230-3236.
99. Slotte J.P., Bierman E.L. Depletion of plasma-membrane sphingomyelin rapidly alters the distribution of cholesterol between plasma membranes and intracellular cholesterol pools in cultured fibroblasts. Biochem. J. 1988, 250:653-658.
100. Gouaze V., Mirault M.E., Carpentier S., Salvayre R., Levade T., Andrieu-Abadie N. Glutathione peroxidase-1 overexpression prevents ceramide production and partially inhibits apoptosis in doxorubicin-treated human breast carcinoma cells. Mol. Pharmacol. 2001, 60:488-496.
101. Kartal Yandim M., Apohan E., Baran Y. Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer. Cancer Chemother. Pharmacol. 2013, 71:13-20.
102. Gouaze V., Liu Y.Y., Prickett C.S., Yu J.Y., Giuliano A.E., Cabot M.C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 2005, 65:3861-3867.
103. Liu Y.Y., Han T.Y., Giuliano A.E., Cabot M.C. Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J. Biol. Chem. 1999, 274:1140-1146.
104. Kunjachan S., Blauz A., Mockel D., Theek B., Kiessling F., Etrych T., Ulbrich K., Van Bloois L., Storm G., Bartosz G., Rychlik B., Lammers T. Overcoming cellular multidrug resistance using classical nanomedicine formulations. Eur. J. Pharm. Sci. 2012, 45:421-428.
105. Takahashi T., Furuchi T., Naganuma A. Endocytic Ark/Prk kinases play a critical role in adriamycin resistance in both yeast and mammalian cells. Cancer Res. 2006, 66:11932-11937.
106. Shen D.W., Su A., Liang X.J., Pai-Panandiker A., Gottesman M.M. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br. J. Cancer 2004, 91:270-276.
107. Chauhan S.S., Liang X.J., Su A.W., Pai-Panandiker A., Shen D.W., Hanover J.A., Gottesman M.M. Reduced endocytosis and altered lysosome function in cisplatin-resistant cell lines. Br. J. Cancer 2003, 88:1327-1334.
108. Grosch S., Schiffmann S., Geisslinger G. Chain length-specific properties of ceramides. Prog. Lipid Res. 2012, 51:50-62.
109. Koivusalo M., Jansen M., Somerharju P., Ikonen E. Endocytic trafficking of sphingomyelin depends on its acyl chain length. Mol. Biol. Cell 2007, 18:5113-5123.
110. Wang T.Y., Silvius J.R. Different sphingolipids show differential partitioning into sphingolipid/cholesterol-rich domains in lipid bilayers. Biophys. J. 2000, 79:1478-1489.
111. Hao M.M., Mukherjee S., Sun Y., Maxfield F.R. Effects of cholesterol depletion and increased lipid unsaturation on the properties of endocytic membranes. J. Biol. Chem. 2004, 279:14171-14178.
112. Milane L., Duan Z.F., Amiji M. Pharmacokinetics and biodistribution of lonidamine/paclitaxel loaded, EGFR-targeted nanoparticles in an orthotopic animal model of multi-drug resistant breast cancer. Nanomedicine 2011, 7:435-444.
113. Galmarini C.M., Warren G., Senanayake M.T., Vinogradov S.V. Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs. Int. J. Pharm. 2010, 395:281-289.
114. Liang X.J., Meng H., Wang Y., He H., Meng J., Lu J., Wang P.C., Zhao Y., Gao X., Sun B., Chen C., Xing G., Shen D., Gottesman M.M., Wu Y., Yin J.J., Jia L. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:7449-7454.
115. Pan L., Liu J., He Q., Wang L., Shi J. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles. Biomaterials 2013, 34:2719-2730.
116. Peetla C., Rao K.S., Labhasetwar V. Relevance of biophysical interactions of nanoparticles with a model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol. Pharm. 2009, 6:1311-1320.
117. Batrakova E.V., Kabanov A.V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J. Control. Release 2008, 130:98-106.
118. Batrakova E.V., Li S., Brynskikh A.M., Sharma A.K., Li Y., Boska M., Gong N., Mosley R.L., Alakhov V.Y., Gendelman H.E., Kabanov A.V. Effects of pluronic and doxorubicin on drug uptake, cellular metabolism, apoptosis and tumor inhibition in animal models of MDR cancers. J. Control. Release 2010, 143:290-301.
119. Janmey P.A., Kinnunen P.K. Biophysical properties of lipids and dynamic membranes. Trends Cell Biol. 2006, 16:538-546.
120. Vogel V., Sheetz M. Local force and geometry sensing regulate cell functions. Nat. Rev. Mol. Cell Biol. 2006, 7:265-275.
121. Wu F., Shao Z.Y., Zhai B.J., Zhao C.L., Shen D.M. Ultrasound reverses multidrug resistance in human cancer cells by altering gene expression of ABC transporter proteins and Bax protein. Ultrasound Med. Biol. 2011, 37:151-159.
122. Yoshida T., Kondo T., Ogawa R., Feril L.B., Zhao Q.L., Watanabe A., Tsukada K. Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells. Cancer Chemother. Pharmacol. 2008, 61:559-567.
123. Schuldes H., Dolderer J.H., Schoch C., Bickeboller R., Woodcock B.G. Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy. Int. J. Clin. Pharmacol. Ther. 2000, 38:204-208.
124. Dolderer J.H., Zimmer G., Woodcock B.G., Bockhorn H., Bickeboller R., Schuldes H. Resistance modulation in CHO cells by R-verapamil and bile salts is associated with physical and chemical changes in the cell membrane. Int. J. Clin. Pharmacol. Ther. 2000, 38:196-203.
125. Ramu A., Ramu N., Rosario L.M. Circumvention of multidrug-resistance in P388 cells is associated with a rise in the cellular content of phosphatidylcholine. Biochem. Pharmacol. 1991, 41:1455-1461.
126. Peetla C., Stine A., Labhasetwar V. Biophysical interactions with model lipid membranes: applications in drug discovery and drug delivery. Mol. Pharm. 2009, 6:1264-1276.
127. Peetla C., Labhasetwar V. Effect of molecular structure of cationic surfactants on biophysical interactions of surfactant-modified nanoparticles with a model membrane and cellular uptake. Langmuir 2009, 25:2369-2377.
128. Deserno M., Gelbart W.M. Adhesion and wrapping in colloid-vesicle complexes. J. Phys. Chem. B 2002, 106:5543-5552.
129. Xu A., Yao M., Xu G., Ying J., Ma W., Li B., Jin Y. A physical model for the size-dependent cellular uptake of nanoparticles modified with cationic surfactants. Int. J. Nanomed. 2012, 7:3547-3554.
130. Hilgemann D.W., Fine M. Mechanistic analysis of massive endocytosis in relation to functionally defined surface membrane domains. J. Gen. Physiol. 2011, 137:155-172.
131. Fine M., Llaguno M.C., Lariccia V., Lin M.J., Yaradanakul A., Hilgemann D.W. Massive endocytosis driven by lipidic forces originating in the outer plasmalemmal monolayer: a new approach to membrane recycling and lipid domains. J. Gen. Physiol. 2011, 137:137-154.
132. Sharma B., Peetla C., Adjei I.M., Labhasetwar V. Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett. 2013, 334:228-236.
133. Demircan B., Dyer L.M., Gerace M., Lobenhofer E.K., Robertson K.D., Brown K.D. Comparative epigenomics of human and mouse mammary tumors. Genes Chromosom. Cancer 2009, 48:83-97.
134. Lu S., Labhasetwar V. Drug resistant breast cancer cell line displays cancer stem cell phenotype and responds sensitively to epigenetic drug SAHA. Drug Deliv. Transl. Res. 2013, 3:183-194.